Chugai Pharmaceutical Co., Ltd. (CHGCY) Q1 2026 Earnings Call April 24, 2026 5:00 AM EDT
Company Participants
Kae Miyata - Head of Corporate Communications Department
Osamu Okuda - President, CEO & Chairman
Tsukasa Kusano - Executive VP and Head of Project & Lifecycle Management Unit
Iwaaki Taniguchi - Senior Executive Officer, CFO, Head of Finance & Director
Junichi Takano - Head of Marketing & Sales Division
Conference Call Participants
Hidemaru Yamaguchi - Citigroup Inc., Research Division
Seiji Wakao - JPMorgan Chase & Co, Research Division
Shinichiro Muraoka - Morgan Stanley, Research Division
Tony Ren - Macquarie Research
Kazuaki Hashiguchi - Daiwa Securities Co. Ltd., Research Division
Akinori Ueda - Goldman Sachs Group, Inc., Research Division
Presentation
Kae Miyata
Head of Corporate Communications Department
Thank you very much for taking time out of your very busy schedules to attend our first quarter FY 2026 earnings call. My name is Miyata from Corporate Communication and IR Department, and I'll be serving as the moderator today. Thank you for your kind attention.
The session will be conducted via Zoom webinar. We will proceed according with the agenda shown on Page 3 of the presentation materials. The briefing will be conducted in Japanese, but we will have simultaneous interpretation in English also available. [Operator Instructions].
First, Dr. Okuda to provide an overview of the first quarter of FY 2026.
Osamu Okuda
President, CEO & Chairman
I am Okuda, President and CEO. I would like to give an overview of the first quarter of FY 2026. Please refer to Slide 5 in the material at hand. In first quarter FY 2026, both domestic and overseas product sales progressed steadily, resulting in both increase in revenue and profit. Growth was driven mainly by Hemlibra exports to Roche as well as increased NEMLUVIO exports and higher royalty income from Galderma.
As a result, compared with the
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。